Clinical Trial

A Study to Evaluate the Safety and Preliminary Signs of Efficacy of [177Lu]Lu-OncoFAP-23 Alone or in Combination With L19-IL2 as a Treatment of Metastatic FAP-positive Solid Tumors

Study acronym: TheraTri
Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess the safety of \[177Lu\]Lu-OncoFAP-23 alone or in combination with L19-IL2 for the treatment of advanced/metastatic Fibroblast Activation Protein (FAP)-positive solid tumors and to establish a Recommended Dose (RD).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-10-10; most recent amendment 2026-01-13.
Status change: Not Yet Recruiting → Recruiting 2026-01-13
Trial Details
NCT Number NCT06640413
Lead Sponsor Philogen S.p.A.
Conditions FAP
Enrollment 56 participants
Start Date 2025-10-31
Primary Completion 2028-05-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-14